Chronic Brain Ischemia. Current State of the Problem

Антипенко, Е. А.; Густов, А. В.

doi:10.21518/2079-701x-2016-19-38-43

Cited by 10 publications

(1 citation statement)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Key words: experimental ischemia, 2-ethyl-6-methyl-3-hydroxypyridine succinate, pathogenetic treatment, ischemic brain damage pharmacocorrection Сосудистая патология мозга является одной из ведущих причин летальности, главной причиной инвалидности, снижения качества жизни в мире [1]. За последние 10-15 лет в Украине отмечается стойкая тенденция к увеличению распространенности и заболеваемости цереброваскулярной патологии (ЦВП), особенно хрони чес ких прогрессирующих форм, что связано с ростом различных экстремальных воздействий [2], изменениями состояния окружающей среды, питания, недостаточной реализацией программ профилактики артериальной гипертонии и атеросклероза, сахарного диабета, дислипидемии, эндотелиальной дисфункции и других ведущих факторов патогенеза ЦВП [3,4]. При этом необходимо отметить, что многие проявления ЦВП достаточно рано формируют клини чес кие синдромы, которые приводят к социально-бытовой дезадаптации.…”

unclassified

Experimental justifi cation and dependent eff ects of therapy by the mexicor of ischemic brain injection in rats

Stoyanov¹,

Vastyanov²,

Kolesnyk³

et al. 2019

UVP

View full text Add to dashboard Cite

Brain vascular pathology is one of the leading causes of mortality, the main cause of disability and life quality decrease throughout the world. Ukraine demonstrate a steady tendency to increase the prevalence and incidence of cerebrovascular pathology over the past 10—15 years, especially chronic progressive forms. Oxidative stress is one of the leading ischemic brain damage cause. To suppress it the main modern approaches in cerebrovascular pathology pharmacological treatment search are connected. The use of the antioxidant 2-ethyl- 6-methyl-3-hydroxypyridine succinate as a pathogenetically necessary agent in conditions of ischemic brain damage during bilateral occlusion of the common carotid arteries in rats in order to study the eff ectiveness of therapy is experimentally substantiated in the article. 4 groups of animals were used in experimental conditions. Rats motor activity in the "open fi eld" test, trembling and stiff ness, a "humpiness" symptom, muscular activity and neurological status were determined on the 2nd, 5th, 7th, 14th and 28th days of the experimental trials. Rats after reproducing ischemia of the brain showed hypokinesia, discoordination, muscle rigidity, severe neurological defi ciency. Mexicor administered in doses of 50 mg/kg and 100 mg/kg contributed to a dose-dependent decreasing of the studied indexes. The eff ectiveness of using mexicor signifi cantly exceeded the results obtained in the group without treatment. A dose-dependent eff ect was recorded with a signifi cant diff erence with increasing dosage. Thus, behavioral, muscular, coordinative and neurological correlates of chronic cerebral ischemia induced by carotid arteries occlusion gone during 14—28 days in conditions of mexicor efficacy. The experimental results obtained are the background for a clinical examinations further series of patients with chronic cerebral ischemia using Mexicor as one of the components of ischemic brain damage complex pathogenetically based pharmacocorrection. Key words: experimental ischemia, 2-ethyl-6-methyl-3-hydroxypyridine succinate, pathogenetic treatment, ischemic brain damage pharmacocorrection

show abstract

unclassified

Experimental justifi cation and dependent eff ects of therapy by the mexicor of ischemic brain injection in rats

Stoyanov¹,

Vastyanov²,

Kolesnyk³

et al. 2019

UVP

View full text Add to dashboard Cite

show abstract

Evaluation of the impact of high-tone therapy on cognitive disorders and quality of life in the complex treatment of patients with comorbid pathology

Шмакова¹,

PANINA

Mykhaylenko

2021

Balneo and PRM Research Journal

View full text Add to dashboard Cite

Introduction. Comorbidity is an independent risk factor for mortality and significantly influences the prognosis and quality of life. Purpose: to evaluate the impact of high-tone HiTOP 4 touch therapy on cognitive disorders and quality of life in the complex treatment of patients with comorbid pathology. Methods: complex treatment of 2 groups of patients with inclusion in the basic treatment regimen of high-tone therapy was carried out - a total of 80 patients (men - 34, women - 46) aged 41 to 79 years old, group I - patients with hypertension and chronic cerebral ischemia (CСI) - 38 patients and group II - patients with hypertension, CСI and concomitant diabetes mellitus (DM) type 2 - 42 patients. The average age in group I was 61.5, in group II - 65.5. Group I received lisinopril and amlodipine in one tablet, group II received metformin in addition to the above therapy. Both groups received a course of 10 sessions of high-tone therapy using the device HiTOP 4 touch (Germany) according to the general method: 2 electrodes on the feet, 2 on the forearms and one on the neck-collar area. All the patients were assessed for their cognitive condition, degree of anxiety and depression, and estimated for quality of life before and after a course of high-tone therapy. In order to do this, we used valid assessment tests, such as the Montreal Cognitive Assessment Scale (MoCA), the Hospital Anxiety and Depression Scale (HADS), and the SF-36 Quality of Life Questionnaire. Results: the course of high-tone therapy for patients with hypertension and CCI led to improved quality of life, on all indicators of the SF-36 scale, except for pain intensity, increased cognitive functions by 3.52 points on the MoCA scale, reduced anxiety by 2.06 points and depression by 1.92 points on the HADS scale. The course of high-tone therapy for patients with CCI, hypertension and type 2 DM resulted in a significant improvement of 5 out of 8 quality of life indicators on the SF-36 scale, cognitive functions by 2.27 points on the MoCA scale and reduced anxiety by 4.3 points, and depression by 0.53 points on the HADS scale. Conclusion: the inclusion of high-tone therapy in the complex treatment of patients with comorbid pathology improves cognitive functions, reduces anxiety and depression, improves quality of life. Keywords: comorbid pathology, high-tone therapy, cognitive functions, anxiety, depression, quality of life,

show abstract

Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT

Parfenov¹,

Zhivolupov²,

Nikulina³

et al. 2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Cognitive disorders were identified in 90.7% of patients (<26 MoCA scores). After treatment, the mean MoCA score increased from 19.58±5.13 to 23.99±4.21 (p<0.0001), the number of patients with normal cognitive functions rate (≥26 scores) increased from 9.3 to 41.3%, the number of patients with marked cognitive impairment decreased. The drug was well-tolerated by old and very old patients, adverse events were observed rarely (0.6% of cases). The majority of doctors (88.4%) noticed the effect of divaza as significant improvement or improvement, and 89.6% of patients valued the effect to be excellent or good. The use of divaza, the drug with endothelioprotective and nootropic effects, is pathogenetically justified and promising in patients with cognitive disorders of vascular etiology.

show abstract

Chronic Brain Ischemia. Current State of the Problem

Cited by 10 publications

References 3 publications

Experimental justifi cation and dependent eff ects of therapy by the mexicor of ischemic brain injection in rats

Experimental justifi cation and dependent eff ects of therapy by the mexicor of ischemic brain injection in rats

Evaluation of the impact of high-tone therapy on cognitive disorders and quality of life in the complex treatment of patients with comorbid pathology

Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT

Contact Info

Product

Resources

About